CancerLinQ LLC, a nonprofit subsidiary of ASCO, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives, are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
A new JCO Precision Oncology article co-authored by CancerLinQ® Deputy Medical Director Wendy Rubinstein, MD, PhD, FACMG, FACP, and CancerLinQ LLC Medical Director Robert S. Miller, MD, FACP, FASCO, published October 1 examines next-generation sequencing in relation to how it can be implemented into the clinical workflow in a practice setting.
ASCO, CancerLinQ LLC and its technology collaborator Concerto HealthAI, and data from the practices that participate in the CancerLinQ® platform will be a part of the upcoming “8th Annual Blueprint for Breakthrough Forum—Validating Real-World Endpoints for an Evolving Regulatory Landscape” forum hosted by Friends of Cancer Research on September 18 in Washington, D.C.
On August 15, ASCO announced the three recipients of its CancerLinQ Discovery® Research Support Grant, each of whom will undertake research projects using data from CancerLinQ Discovery®, an offering of ASCO’s CancerLinQ® initiative that provides de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.
In an effort to advance cancer data sharing and improve the quality and coordination of patient care, three of the nation’s leading health and technology organizations have established a core set of data elements and recommended technical specifications (the Minimal Common Oncology Data Elements, or “mCODE”) that are essential for capturing and reporting the characteristics, treatments, and outcomes of every cancer patient and should be contained in each patient’s electronic health record (EHR). The mCODE™ initiative, a collaboration between ASCO®, its wholly owned nonprofit subsidiary CancerLinQ LLC, the MITRE Corporation, and the Alliance for Clinical Trials in Oncology Foundation (Alliance Foundation), released the initial set of common cancer data standards and specifications today at ASCO’s 2019 Annual Meeting in Chicago and published them online at mCODEinitiative.org.
CancerLinQ LLC hosted a webinar on May 16, that showed new tools within the CancerLinQ® platform that allow for automated quality reporting to the Merit-based Incentive Payment System (MIPS) and ASCO’s QOPI Certification Program.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, announced today that CureMD’s Electronic Health Record (EHR) system is the third to be certified by CancerLinQ® after meeting criteria for interoperability and data standardization. This collaboration will streamline access to CancerLinQ® and drive interoperability among EHR systems.
The number of electronic health record (EHR) systems joining with CancerLinQ to facilitate information sharing continues to grow. CancerLinQ LLC, a wholly owned nonprofit subsidiary of the ASCO, announced today that Varian’s ARIA® Oncology Information System (OIS) is the next Electronic Health Record (EHR) System to be certified by CancerLinQ® after meeting criteria for interoperability and data standardization. This collaboration aims to dismantle barriers to information sharing and streamline access to CancerLinQ for oncology practices using Varian ARIA® OIS.
ASCO’s first draft of its data specification of the Minimal Common Oncology Data Elements (mCODE™) project is available and open for comment. The deadline for comments has been extended by one week and now closes on February 19.
Suanna Bruinooge, MPH, Division Director, Research Strategy and Operations for ASCO’s Center for Research and Analytics, recently spoke about the TAPUR™ Study and the importance of data collection in expanded access (individual use, as well as medium, and large programs) as part of a panel discussion for a summit “Integrating Expanded Access Into the Modern Drug Development Process.”
A new global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes will help inform the understanding of cancer risk. Wendy Rubinstein, MD, PhD, FACP, FACMG, and Deputy Medical Director of CancerLinQ, LLC, a wholly owned nonprofit subsidiary of ASCO, served as a co-author of the new paper published this week in PLOS Genetics detailing the development of the new resource, BRCA Exchange.